BRNS Share Price Performance
Recent BRNS News & Updates
No updates
Barinthus Biotherapeutics plc Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.62
- Gross Margin
- 107.35%
- Net Profit Margin
- -435.79%
- Debt/Equity Ratio
- 0%
Barinthus Biotherapeutics plc Competitors
About BRNS
- Founded
- 2016
- Employees
- 105
- CEO
- WebsiteView website
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
U.K. Market Performance
- 7 Days: -2.5%
- 3 Months: 17.1%
- 1 Year: 12.4%
- Year to Date: 12.2%
Over the last 7 days, the market has dropped 4.2%, driven by a loss of 5.7% in the Energy sector. In the last year, the market is actually up 7.7%. Earnings are forecast to grow by 14% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading